<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:cas="http:///uima/cas.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:type="http:///org/apache/uima/trials/type.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <tcas:DocumentAnnotation xmi:id="1" sofa="6" begin="0" end="1881" language="x-unspecified"/>
    <type:ORR xmi:id="13" sofa="6" begin="1407" end="1410"/>
    <type:PFSTime xmi:id="17" sofa="6" begin="1612" end="1618"/>
    <type:PFSTime xmi:id="37" sofa="6" begin="1678" end="1684"/>
    <type:PFSRate xmi:id="21" sofa="6" begin="1641" end="1644"/>
    <type:PFSRate xmi:id="41" sofa="6" begin="1707" end="1710"/>
    <type:OSRate xmi:id="25" sofa="6" begin="1650" end="1654"/>
    <type:OSRate xmi:id="45" sofa="6" begin="1715" end="1718"/>
    <type:OSTime xmi:id="29" sofa="6" begin="1612" end="1618"/>
    <type:OSTime xmi:id="33" sofa="6" begin="1678" end="1684"/>
    <cas:Sofa xmi:id="6" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="BACKGROUND: In this pilot study, the authors assessed the feasibility of&#13;&#10;combination epratuzumab and rituximab plus cyclophosphamide, doxorubicin,&#13;&#10;vincristine, and prednisone (ER-CHOP) in patients with newly diagnosed diffuse&#13;&#10;large B-cell lymphoma (DLBCL).&#13;&#10;METHODS: Patients received chemotherapy on the following schedule: epratuzumab&#13;&#10;360 mg/m2, rituximab 375 mg/m2, and standard-dose CHOP every 3 weeks for 6 to 8&#13;&#10;cycles. The primary endpoint was the incidence of grade 4 neutropenia and grade 3&#13;&#10;or 4 antibody infusional toxicity. Secondary endpoints were the complete response&#13;&#10;(CR) rate, the overall response rate (ORR), and progression-free survival (PFS). &#13;&#10;Weekly blood counts were obtained to monitor hematologic toxicity. Fifteen&#13;&#10;patients were enrolled and treated. Baseline patient characteristics included a&#13;&#10;median age of 63 years (range, 42-78 years), 60% of patients had stage III or IV &#13;&#10;disease, 7 patients had a low-risk International Prognostic Index (IPI) score (0 &#13;&#10;or 1), 7 patients had an intermediate-risk IPI score (2 or 3), and 1 patient was &#13;&#10;high risk.&#13;&#10;RESULTS: Grade 3 or 4 neutropenia was observed in 14 patients (93%) or in 28 of&#13;&#10;92 treatment cycles (30%). Three patients developed grade &gt; or =3 infection or&#13;&#10;fever. Eleven patients (73%) required dose reductions. No grade 3 antibody&#13;&#10;infusion-related toxicity was reported. Thirteen of 15 patients responded (ORR,&#13;&#10;87%,), including 10 CRs (67%), 3 partial responses (20%), 1 patient with stable&#13;&#10;disease, and 1 patient with disease progression. At a median follow-up of 30&#13;&#10;months, 13 of 15 patients remained alive. The 1-year PFS and OS rates were 93%&#13;&#10;and 100%, respectively; and the 2-year PFS and OS rates were 86% and 86%,&#13;&#10;respectively.&#13;&#10;CONCLUSIONS: ER-CHOP every 21 days was feasible as treatment for newly diagnosed &#13;&#10;patients with DLBCL. A Phase II multicenter study is underway."/>
    <cas:View sofa="6" members="1 13 17 37 21 41 25 45 29 33"/>
</xmi:XMI>
